Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges
Foundation offers COVID-19 testing and support to more than 2.1 million students as part of campus health services
Through the Foundation’s CollegeBuys program, Biocept’s PCR-based COVID-19 test is now available for community colleges to purchase for students, faculty and staff. Access to and availability of testing will provide information needed to help protect the safety of campus populations and reduce the spread of the virus on campuses and in surrounding communities if/when colleges return from the current remote learning environment as a result of the COVID-19 pandemic.
“As colleges prepare for in-person instruction, COVID-19 testing is going to be critically important in keeping campuses and students healthy and safe,” said
“Expanding access to COVID-19 testing supplies is essential to smart and safe reopening strategies for the California Community Colleges—safeguarding the health and wellness of our students, faculty and staff,” said
This partnership and the access to COVID-19 testing for the colleges are made possible through the Foundation’s CollegeBuys program, the systemwide procurement vehicle which leverages the purchasing power of the 116 colleges to offer a number of services and products at up to 85% discount, ensuring colleges can meet the educational needs of students.
About the
The
About CollegeBuys
CollegeBuys is the Foundation’s systemwide procurement vehicle that leverages the buying power of California’s 116 community colleges to offer discounts of up to 85 percent on a wide range of educational products—from industry-leading software and technology to high quality office and classroom furniture. For more information, visit www.collegebuys.org.
About
Forward-Looking Statements
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005228/en/
Media Contact:
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact:
Jcain@lhai.com, 310-691-7100
Source: